Since Crkl enhances the migration of leukemic cells and promotes the development of leukemia (Uemura and Griffin, 1999; Kardinal et al., 2000; Hemmeryckx et al., 2001), the combination of Crkl and DOCK2 may be the one of the therapeutic targets for leukemia (Nishihara et al., 2002). This evidence concerns the gene DOCK2 and leukemia.